journal
https://read.qxmd.com/read/38336529/cd19-car-t-cell-therapy-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-why-does-it-fail
#21
JOURNAL ARTICLE
Hannah Kinoshita, Catherine M Bollard, Keri Toner
Chimeric antigen receptor T (CAR-T) cell therapy is an effective treatment for relapsed or refractory diffuse large B cell lymphoma (DLBCL) with 3 CD19 targeting products now FDA-approved for this indication. However, up to 60% of patients ultimately progress or relapse following CAR-T cell therapy. Mechanisms of resistance to CAR-T cell therapy in patients with DLBCL are likely multifactorial and have yet to be fully elucidated. Determining patient, tumor and therapy-related factors that may predict an individual's response to CAR-T cell therapy requires ongoing analysis of data from clinical trials and real-world experience in this population...
December 5, 2023: Seminars in Hematology
https://read.qxmd.com/read/38151380/biological-heterogeneity-in-diffuse-large-b-cell-lymphoma
#22
JOURNAL ARTICLE
Laura K Hilton, David W Scott, Ryan D Morin
Diffuse large B-cell lymphoma (DLBCL) is heterogeneous both in clinical outcomes and the underlying disease biology. Over the last 2 decades, several different approaches for dissecting biological heterogeneity have emerged. Gene expression profiling (GEP) stratifies DLBCL into 3 broad groups (ABC, GCB, and DZsig/MHG), each with parallels to different normal mature B cell developmental states and prognostic implications. More recently, several different genomic approaches have been developed to categorize DLBCL based on the co-occurrence of tumor somatic mutations, identifying more granular biologically unified subgroups that complement GEP-based approaches...
December 1, 2023: Seminars in Hematology
https://read.qxmd.com/read/38151379/biological-prognostic-and-therapeutic-impact-of-the-epigenome-in-cll
#23
JOURNAL ARTICLE
Alba Maiques-Diaz, Jose Ignacio Martin-Subero
Chronic lymphocytic leukemia (CLL) is characterized by widespread alterations in the genetic and epigenetic landscapes which seem to underlie the variable clinical manifestations observed in patients. Over the last decade, epigenomic studies have described the whole-genome maps of DNA methylation and chromatin features of CLL and normal B cells, identifying distinct epigenetic mechanisms operating in tumoral cells. DNA methylation analyses have identified that the CLL methylome contains imprints of the cell of origin, as well as of the proliferative history of the tumor cells, with both being strong independent prognostic predictors...
December 1, 2023: Seminars in Hematology
https://read.qxmd.com/read/38135609/evidence-based-management-of-primary-and-secondary-cns-lymphoma
#24
JOURNAL ARTICLE
Jahanzaib Khwaja, Lakshmi Nayak, Kate Cwynarski
Central nervous system (CNS) lymphoma has traditionally had very poor outcomes however advances in management have resulted in dramatic improvements and long-term survival of patients. We describe the evidence for treatment strategies for these aggressive disorders. In primary CNS lymphoma there are randomized trial data to inform treatment decisions but these are lacking to guide management in secondary CNS lymphoma. Dynamic assessment of patient fitness and frailty is key throughout treatment, alongside delivery of CNS-bioavailable therapy and enrolment in clinical trials, at each stage of the disease...
December 1, 2023: Seminars in Hematology
https://read.qxmd.com/read/38242772/epidemiology-and-etiology-of-diffuse-large-b-cell-lymphoma
#25
JOURNAL ARTICLE
Sophia S Wang
As the most common non-Hodgkin lymphoma subtype, diffuse large B-cell lymphoma (DLBCL) incidence patterns generally parallel that for NHL overall. Globally, DLBCL accounts for a third of all NHLs, ranging between 20% and 50% by country. Based on United States (U.S.) cancer registry data, age-standardized incidence rate for DLBCL was 7.2 per 100,000. DLBCL incidence rises with age and is generally higher in males than females; in the U.S., incidence is highest among non-Hispanic whites (9.2/100,000). Like NHL incidence, DLBCL incidence rose in the first half of the 20th century but has largely plateaued...
November 27, 2023: Seminars in Hematology
https://read.qxmd.com/read/38072722/antibody-and-immunotherapy-in-diffuse-large-b-cell-lymphoma
#26
JOURNAL ARTICLE
Allison Barraclough, Eliza A Hawkes
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma and a heterogeneous B-cell disease. The majority of patients with newly diagnosed disease are cured with first-line combination immunochemotherapy treatment however, those who experience treatment failure have dismal outcomes. Antibody therapies and immunotherapy have provided the single most major advance in the treatment of DLBCL in the last 4 decades. Rituximab, the first immunotherapy, and a monoclonal antibody targeting CD20, improved DLBCL overall survival when added to chemotherapy 2 decades ago...
November 23, 2023: Seminars in Hematology
https://read.qxmd.com/read/38072721/dlbcl-arising-from-indolent-lymphomas-how-are-they-different
#27
JOURNAL ARTICLE
Erin M Parry, Sandrine Roulland, Jessica Okosun
Transformation to diffuse large B-cell lymphoma (DLBCL) is a recognized, but unpredictable, clinical inflection point in the natural history of indolent lymphomas. Large retrospective studies highlight a wide variability in the incidence of transformation across the indolent lymphomas and the adverse outcomes associated with transformed lymphomas. Opportunities to dissect the biology of transformed indolent lymphomas have arisen with evolving technologies and unique tissue collections enabling a growing appreciation, particularly, of their genetic basis, how they relate to the preceding indolent lymphomas and the comparative biology with de novo DLBCL...
November 23, 2023: Seminars in Hematology
https://read.qxmd.com/read/38326145/introduction-to-series-diffuse-large-b-cell-lymphoma
#28
EDITORIAL
Sonali M Smith, Laura Pasqualucci
No abstract text is available yet for this article.
November 2023: Seminars in Hematology
https://read.qxmd.com/read/37863704/debate-should-the-loss-of-disability-adjusted-life-years-daly-define-the-focus-of-global-hematology-the-case-for-prioritizing-capacity-building-in-anemia-management-and-blood-transfusion
#29
JOURNAL ARTICLE
David J Roberts, Aggrey Dhabangi
Setting priorities in healthcare is always contentious given the array of possible services at primary, secondary, and tertiary levels of care, not to mention potential public health interventions. The central goals in global policy have been reducing inequity within and between countries, protecting vulnerable groups (particularly women and children) and reducing the major communicable diseases which have historically been a major burden in lower- and middle-income countries. Here limited relative and absolute spending on healthcare have spurred a series of initiatives in Global Health over the last 50 years which have led to significant gains in measures of morbidity and mortality...
September 30, 2023: Seminars in Hematology
https://read.qxmd.com/read/37838581/special-edition-of-the-seminars-in-hematology-series-on-global-hematology-care
#30
EDITORIAL
Anna Schuh
No abstract text is available yet for this article.
September 27, 2023: Seminars in Hematology
https://read.qxmd.com/read/37806793/the-future-of-aplastic-anemia-treatment-in-brazil-lessons-learned-for-global-hematology
#31
JOURNAL ARTICLE
Rodrigo T Calado
Aplastic anemia (AA) is a rare serious hematologic disorder caused by hematopoietic stem cell failure in maintaining hematopoiesis. AA is virtually fatal if not treated, and diagnosis and therapy require extensive hematologic infrastructure. Academic medical centers in Brazil have continuously and significantly contributed to diagnostic tools and therapy development, from novel transplant strategies to drug combinations and implementation science in the national public health system. In the present review, we discuss how the collaborative effort among academic centers in hematology has contributed to improving health care for patients with aplastic anemia...
September 24, 2023: Seminars in Hematology
https://read.qxmd.com/read/37723025/the-case-for-prioritizing-malignant-hematology-services-in-low-and-middle-income-countries
#32
JOURNAL ARTICLE
Satish Gopal
A clear case for can be made for prioritizing malignant hematology services in low- and middle-income countries based on large public health burden, convincing demonstrations of cure and control, innovation opportunities with likely worldwide implications, and sizable returns on investment for health systems and societies. We must now ensure that need and opportunity are matched by commensurate levels of investment and attention.
September 2, 2023: Seminars in Hematology
https://read.qxmd.com/read/37770365/how-to-set-up-a-clinical-research-center-in-brazil-as-an-example-of-a-middle-income-country
#33
JOURNAL ARTICLE
Eduardo Flávio Oliveira Ribeiro, Ana Amélia Morais de Lacerda Mangueira Belmiro, Lenisa Cezar Vilas Boas, Carsten Utoft Niemann
In health care, innovation is a core part of the process that pushes advances forward. Drug and device development follow a step-by-step process from the discovery of a molecule to the final product. While patent filing and preclinical studies are usually performed by academic centers or start-ups, the clinical development is usually performed by pharmaceutical companies. To assess safety, efficacy and fulfil regulatory demands, clinical trials must be performed in sequential Phase I, II, and III stages prior to market access...
September 2023: Seminars in Hematology
https://read.qxmd.com/read/37723024/forging-international-collaboration-and-alliances-to-establish-the-largest-transplant-center-in-the-north-of-vietnam
#34
JOURNAL ARTICLE
Bach Quoc Khanh, Vo Thi Thanh Binh, Nguyen Ha Thanh, Dao Phan Thu Huong, Do Thi Thuy, Nguyen Khanh Ha, Richard W Childs
Through collaboration with international experts, our institution established a highly active and successful hematopoietic stem cell transplant program, providing access to this potentially curative treatment modality for patients with a variety of benign and malignant hematological diseases. The initial development of an autologous stem cell transplant program provided our institution with the infrastructure, equipment, and expertise needed for the subsequent development of an allogeneic stem cell transplant program...
September 1, 2023: Seminars in Hematology
https://read.qxmd.com/read/37596119/the-future-of-lymphoma-diagnosis-prognosis-and-treatment-monitoring-in-countries-with-limited-access-to-pathology-services
#35
JOURNAL ARTICLE
Clara Chamba, William Mawalla
The world is moving towards precision medicine for cancer. This movement goes hand in hand with the development of newer advanced technologies for early, precise diagnosis of cancer and personalized treatment plans with fewer adverse effects for the patient. Liquid biopsy is one such advancement. At the same time, it has the advantage of minimal invasion and avoids serial invasive biopsies. In countries with limited access to pathology services, such as sub-Saharan Africa, liquid biopsy may provide an opportunity for early detection and prognostication of lymphoma...
September 2023: Seminars in Hematology
https://read.qxmd.com/read/37730472/current-challenges-and-new-approaches-to-implementing-optimal-management-of-sickle-cell-disease-in-sub-saharan-africa
#36
JOURNAL ARTICLE
Mwashungi Ally, Emmanuel Balandya
Sickle cell disease (SCD) is the most common life-threatening monogenic disorder in the world. The disease is highly prevalent in malaria endemic areas with over 75% of patients residing in Sub-Saharan Africa (SSA). It is estimated that, without proper care, up to 90% of children with SCD will not celebrate their fifth birthday. Early identification and enrolment into comprehensive care has been shown to reduce the morbidity and mortality related with SCD complications. However, due to resource constraints, the SSA is yet to implement universal newborn screening programs for SCD...
August 24, 2023: Seminars in Hematology
https://read.qxmd.com/read/37620237/special-issue-on-circulating-tumor-dna-introductory-editorial
#37
EDITORIAL
Adalgisa Condoluci, Davide Rossi
No abstract text is available yet for this article.
August 19, 2023: Seminars in Hematology
https://read.qxmd.com/read/37563073/circulating-tumor-dna-in-nk-t-and-peripheral-t-cell-lymphoma
#38
JOURNAL ARTICLE
Yu-Jia Huo, Wei-Li Zhao
Natural killer (NK)/T-cell lymphomas (NK/TCL) and peripheral T-cell lymphomas (PTCL) are aggressive hematological malignancies. With the development of next-generation sequencing, circulating tumor DNA (ctDNA) can be detected by several techniques with clinical implications. So far, the effect of ctDNA in pretreatment prognosis prediction, longitudinal monitoring of treatment response and surveillance of long-term remission or relapse in NK/TCL and PTCL has been reported in several researches.
July 26, 2023: Seminars in Hematology
https://read.qxmd.com/read/37517948/palliative-care-needs-of-patients-with-hematologic-malignancies-and-family-caregivers-and-challenges-of-palliative-care-provision-in-asia-a-review-of-evidence
#39
JOURNAL ARTICLE
Yupawadee Kantabanlang, Cheng-Pei Lin, Kittikorn Nilmanat, Ping Guo
Patients with hematologic malignancies often experience fatigue, lack of vitality, and energy, and high psychological distress. High levels of unmet care needs of patients with hematologic malignancies in Asia were identified. This review provides an overview of current evidence on the experiences and palliative care needs of patients with hematologic malignancies and their families and the barriers and challenges of integrating palliative care into hematology care in Asia. Patients with hematologic malignancies who received palliative care could benefit from less aggressive end-of-life treatments...
July 22, 2023: Seminars in Hematology
https://read.qxmd.com/read/37517949/inequalities-in-access-to-treatment-in-argentina-differences-in-management-of-cll-and-multiple-myeloma
#40
JOURNAL ARTICLE
María José Mela Osorio, Carolina Pavlovsky, Miguel Arturo Pavlovsky
Health equity is today an important objective to evenly reach the population among different health care systems. This article will focus on diagnosis and treatment access inequalities in Argentina. Although different aspects must be optimized to overcome access barriers worldwide, access inequalities in some regions of Argentina may depend basically on the type of health coverage or insurance. Health care in Argentina is divided into Public, Social security and Private care systems. Access to diagnosis and disease monitoring will vary according whether the patient is under each of these systems...
July 15, 2023: Seminars in Hematology
journal
journal
24399
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.